Utah Medical Products Inc UTMD
We take great care to ensure that the data presented and summarized in this overview for UTAH MEDICAL PRODUCTS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding UTMD
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny231KShares$14.9 Million0.02% of portfolio
-
Black Rock Inc. New York, NY197KShares$12.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA181KShares$11.7 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX176KShares$11.4 Million0.0% of portfolio
-
Brandes Investment Partners, LP La Jolla, CA138KShares$8.95 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA97.1KShares$6.28 Million0.0% of portfolio
-
Hotchkis & Wiley Capital Management LLC Los Angeles, CA89KShares$5.76 Million0.02% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX86.6KShares$5.6 Million0.38% of portfolio
-
Rice Hall James & Associates, LLC83.3KShares$5.39 Million0.33% of portfolio
-
State Street Corp Boston, MA80.9KShares$5.23 Million0.0% of portfolio
Latest Institutional Activity in UTMD
Top Purchases
Top Sells
About UTMD
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Insider Transactions at UTMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 18
2024
|
Brian Koopman Principal Financial Officer |
SELL
Bona fide gift
|
Direct |
50
-5.36%
|
$3,550
$71.61 P/Share
|
May 17
2024
|
Paul O Richins Director |
SELL
Bona fide gift
|
Indirect |
225
-1.05%
|
$15,525
$69.72 P/Share
|
Jun 15
2023
|
Brian Koopman Principal Financial Officer |
SELL
Bona fide gift
|
Direct |
60
-6.05%
|
$5,640
$94.31 P/Share
|
May 18
2023
|
Paul O Richins Director |
SELL
Open market or private sale
|
Indirect |
700
-3.16%
|
$65,100
$93.47 P/Share
|
Mar 17
2023
|
Paul O Richins Director |
SELL
Bona fide gift
|
Indirect |
150
-0.67%
|
$13,800
$92.5 P/Share
|
Feb 08
2023
|
Barbara A Payne Director |
SELL
Bona fide gift
|
Direct |
500
-9.37%
|
$45,000
$90.0 P/Share
|
Dec 06
2022
|
Brian Koopman Principal Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+33.51%
|
$37,000
$74.64 P/Share
|
Dec 06
2022
|
Brian Koopman Principal Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
366
-42.66%
|
$36,966
$101.88 P/Share
|
Nov 18
2022
|
Paul O Richins Director |
SELL
Open market or private sale
|
Indirect |
449
-1.97%
|
$40,410
$90.81 P/Share
|
Nov 17
2022
|
Paul O Richins Director |
SELL
Open market or private sale
|
Indirect |
161
-0.7%
|
$14,490
$90.0 P/Share
|
Nov 11
2022
|
Paul O Richins Director |
SELL
Open market or private sale
|
Indirect |
40
-0.17%
|
$3,680
$92.5 P/Share
|
Oct 31
2022
|
Brian Koopman Principal Financial Officer |
SELL
Bona fide gift
|
Direct |
65
-7.04%
|
$5,720
$88.94 P/Share
|
Jun 27
2022
|
Paul O Richins Director |
SELL
Bona fide gift
|
Indirect |
250
-1.08%
|
$22,000
$88.98 P/Share
|
May 11
2022
|
Barbara A Payne Director |
SELL
Open market or private sale
|
Direct |
2,000
-27.26%
|
$170,000
$85.2 P/Share
|
Feb 09
2022
|
Barbara A Payne Director |
SELL
Bona fide gift
|
Direct |
500
-6.38%
|
$49,000
$98.94 P/Share
|
Dec 13
2021
|
Paul O Richins Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
62
+0.27%
|
$3,100
$50.72 P/Share
|
Nov 24
2021
|
Ernst G Hoyer Director |
SELL
Open market or private sale
|
Indirect |
4,900
-49.49%
|
$617,400
$126.41 P/Share
|
Nov 23
2021
|
Ernst G Hoyer Director |
SELL
Open market or private sale
|
Indirect |
100
-1.0%
|
$12,500
$125.01 P/Share
|
Nov 22
2021
|
Kevin L Cornwell Chairman, CEO, Secretary |
SELL
Bona fide gift
|
Indirect |
2,000
-1.05%
|
$248,000
$124.75 P/Share
|
Nov 18
2021
|
Barbara A Payne Director |
SELL
Open market or private sale
|
Direct |
1,249
-13.74%
|
$138,639
$111.06 P/Share
|
Last 12 Months Summary
Bona fide gift | 275 shares |
---|